We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $5.47B
1-Year Est. Return 131.34%
This Fund
S&P 500
This Quarter Est. Return
+6.22%
1 Year Est. Return
+131.34%
3 Year Est. Return
+363.85%
5 Year Est. Return
+515.73%
10 Year Est. Return
+2,786.05%
AUM
$2.72B
AUM Growth
+$29.7M
Cap. Flow
+$221M
Cap. Flow %
8.11%
Top 10 Hldgs %
47.84%
Holding
110
New
9
Increased
24
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$71.7M
2
BHVN icon
Biohaven
BHVN
+$47.3M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$42.1M
4
SYY icon
Sysco
SYY
+$38.9M
5
AAPL icon
Apple
AAPL
+$34.8M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$48M
2
CI icon
Cigna
CI
+$45.6M
3
MCK icon
McKesson
MCK
+$30.5M
4
VZ icon
Verizon
VZ
+$23M
5
BCYC
Bicycle Therapeutics
BCYC
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 59.12%
2 Technology 10.09%
3 Miscellaneous 10%
4 Communication Services 6.22%
5 Consumer Discretionary 5.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
$272M 10%
500,000
+50,000
+11% +$26.2M
BHVN icon
2
Biohaven
BHVN
$2.27B
$180M 6.63%
5,199,219
+1,196,173
+30% +$47.3M
INSM icon
3
Insmed
INSM
$28.1B
$169M 6.21%
2,521,800
+498,800
+25% +$19.3M
KURA icon
4
Kura Oncology
KURA
$1.08B
$146M 5.35%
7,069,627
– –
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$107M 3.94%
1,565,996
+606,798
+63% +$42.1M
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3B
$93M 3.42%
10,004,492
+2,127,195
+27% +$19.2M
RARE icon
7
Ultragenyx Pharmaceutical
RARE
$1.41B
$84.7M 3.11%
2,061,426
+384,615
+23% +$16.4M
META icon
8
Meta Platforms (Facebook)
META
$1.67T
$84.3M 3.1%
167,169
-6,436
-4% -$3.13M
ACLX
9
DELISTED
Arcellx
ACLX
$83.7M 3.07%
1,516,254
-46,100
-3% -$2.51M
UNH icon
10
UnitedHealth
UNH
$353B
$82.2M 3.02%
161,468
+146,345
+968% +$71.7M
AAPL icon
11
Apple
AAPL
$4.6T
$76.5M 2.81%
363,357
+186,677
+106% +$34.8M
AMZN icon
12
Amazon
AMZN
$2.72T
$68.8M 2.53%
356,268
-694
-0.2% -$127K
ETNB
13
DELISTED
89bio
ETNB
$64.3M 2.36%
8,031,845
+1,733,841
+28% +$15.5M
TSM icon
14
TSMC
TSM
$2.26T
$61M 2.24%
350,752
+21,400
+6% +$3.25M
AMD icon
15
Advanced Micro Devices
AMD
$851B
$56.1M 2.06%
345,998
+4,299
+1% +$692K
ELV icon
16
Elevance Health
ELV
$86.1B
$49.5M 1.82%
91,442
+40,517
+80% +$21.4M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$49.4M 1.81%
4,192,005
– –
RPRX icon
18
Royalty Pharma
RPRX
$27B
$49.2M 1.81%
1,866,361
-384,000
-17% -$10.6M
MSFT icon
19
Microsoft
MSFT
$3.65T
$46.5M 1.71%
104,033
+24,716
+31% +$10.4M
EYPT icon
20
EyePoint Inc
EYPT
$374M
$45M 1.65%
5,175,823
+1,411,935
+38% +$19.7M
APO icon
21
Apollo Global Management
APO
$77.3B
$41.9M 1.54%
354,486
-16,150
-4% -$1.83M
T icon
22
AT&T
T
$172B
$41.8M 1.54%
2,186,886
-211,733
-9% -$3.68M
SYY icon
23
Sysco
SYY
$39.1B
$37.2M 1.37%
+520,900
New +$38.9M
CTNM
24
Contineum Therapeutics
CTNM
$570M
$36.2M 1.33%
+2,053,334
New +$33.1M
KO icon
25
Coca-Cola
KO
$377B
$35.7M 1.31%
560,613
+14,113
+3% +$874K
1
2 3 4 5

Similar funds

NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
ENV
Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $5.49B AUM 56.94% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
TPCW
TD Private Client Wealth New York $5.44B AUM 18.56% 1-Year Est. Return

Suvretta Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Suvretta Capital Management held 110 positions worth $2.72B, up 1.1% from $2.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Suvretta Capital Management deployed $221M of net new capital in Q2 2024, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Sysco: 520,900 shares worth $37.2M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier, followed by Technology and Miscellaneous.

On the sell side, the largest reduction was Cigna, an estimated $45.6M trimmed.

  • Suvretta Capital Management's largest Q2 2024 buy was Sysco: 520,900 shares worth $37.2M.
  • Suvretta Capital Management added most to UnitedHealth in Q2 2024, an estimated $71.7M increase.
  • Suvretta Capital Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $45.6M.
  • Suvretta Capital Management fully exited argenx in Q2 2024, selling an estimated $48M.
  • Suvretta Capital Management's ten largest holdings make up 48% of its $2.72B portfolio in Q2 2024.
  • Suvretta Capital Management opened 9 new positions and closed 12 in Q2 2024.
  • Suvretta Capital Management's portfolio value rose 1.1% quarter-over-quarter to $2.72B.

Based on Suvretta Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.